Bupropion hydrochloride; dextromethorphan hydrobromide - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for bupropion hydrochloride; dextromethorphan hydrobromide and what is the scope of patent protection?
Bupropion hydrochloride; dextromethorphan hydrobromide
is the generic ingredient in one branded drug marketed by Axsome and is included in one NDA. There are one hundred and fifteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Bupropion hydrochloride; dextromethorphan hydrobromide has one hundred and eighty-two patent family members in thirty-one countries.
One supplier is listed for this compound.
Summary for bupropion hydrochloride; dextromethorphan hydrobromide
International Patents: | 182 |
US Patents: | 115 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 1 |
DailyMed Link: | bupropion hydrochloride; dextromethorphan hydrobromide at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for bupropion hydrochloride; dextromethorphan hydrobromide
Generic Entry Date for bupropion hydrochloride; dextromethorphan hydrobromide*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, EXTENDED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for bupropion hydrochloride; dextromethorphan hydrobromide
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Medical University of South Carolina | Phase 1 |
See all bupropion hydrochloride; dextromethorphan hydrobromide clinical trials
Pharmacology for bupropion hydrochloride; dextromethorphan hydrobromide
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
AUVELITY | Extended-release Tablet | bupropion hydrochloride; dextromethorphan hydrobromide | 45 mg/105 mg | 215430 | 1 | 2022-12-22 |
US Patents and Regulatory Information for bupropion hydrochloride; dextromethorphan hydrobromide
International Patents for bupropion hydrochloride; dextromethorphan hydrobromide
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 3179048 | UTILISATION DE COMBINAISONS DE BUPROPION ET DE DEXTROMETHORPHANE POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES (USE OF BUPROPION AND DEXTROMETHORPHAN COMBINATIONS FOR TREATING NEUROLOGICAL DISORDERS) | ⤷ Try a Trial |
South Korea | 101931896 | ⤷ Try a Trial | |
Costa Rica | 20200415 | FORMAS Y MÈTODOS DE DOSIS PARA BUPROPIÓN ENANTIOMÉRICAMENTE ENRIQUECIDO O PURO (DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION) | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2019165379 | ⤷ Try a Trial | |
Chile | 2020002166 | Formas de dosificación y métodos para el bupropión enriquecido enantioméricamente o puro. | ⤷ Try a Trial |
Malaysia | 189466 | METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for bupropion hydrochloride; dextromethorphan hydrobromide
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0656775 | CR 2000 00018 | Denmark | ⤷ Try a Trial | PRODUCT NAME: BUPROPIONHYDROCHLORID; NAT. REG. NO/DATE: 31347 20000606; FIRST REG. NO/DATE: NL 24160 19991201 |
0656775 | 28/2000 | Austria | ⤷ Try a Trial | PRODUCT NAME: BUPROPION HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-23680 20000616; FIRST REGISTRATION: NL 24160 19991201 |
2316456 | C201730057 | Spain | ⤷ Try a Trial | PRODUCT NAME: NALTREXONA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, EN PARTICULAR CLORHIDRATO DE NALTREXONA, Y BUPROPION O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR CLORHIDRATO DE BUPROPION.; NATIONAL AUTHORISATION NUMBER: EU/1/14/988; DATE OF AUTHORISATION: 20150326; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/988; DATE OF FIRST AUTHORISATION IN EEA: 20150326 |
0467488 | SPC/GB00/019 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: BUPROPION HYDROCHLORIDE; REGISTERED: NL RVG 24160 19991201; UK PL 10949/0340 20000607 |
2316456 | CR 2017 00062 | Denmark | ⤷ Try a Trial | PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330 |
2316456 | 349 22-2017 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: KOMBINACIA NALTREXONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM A BUPROPIONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/988 20150330 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.